Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03718416
Other study ID # PATH-PWS-001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 28, 2018
Est. completion date January 31, 2024

Study information

Verified date February 2024
Source Foundation for Prader-Willi Research
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

PATH for PWS is a study to help researchers better understand serious medical events in PWS over a 4-year period, as well as evaluate how PWS-related behaviors change over time. The data from this study is intended to inform the development and clinical trial design of potential new treatments.


Description:

Every 6 months, participants or their caregivers will be asked to update online surveys about medical problems and serious medical events, as well as provide information about conditions and behaviors often associated with PWS such as hyperphagia. Because this is an observational study, no study drug will be provided and no visits to a doctor or clinic are required.


Recruitment information / eligibility

Status Completed
Enrollment 700
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria: Participants must meet all of the following criteria: - Confirmed diagnosis of PWS - At least 5 years of age - Live in the United States, Canada, Australia, or New Zealand - Must be enrolled or willing to enroll in the Global PWS Registry (https://pwsregistry.org) Participants or their caregiver must also meet all of the following criteria: - Have access to the internet to complete online surveys at least every 6 months - Agree to receive reminders to complete online surveys - Allow the staff to ask questions about survey responses if more information is needed and to enter data into the surveys Exclusion Criteria: Participants or their caregiver meeting any of the following criteria will be excluded: - Is not able to read and understand English

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Foundation for Prader-Willi Research (FPWR) Walnut California

Sponsors (6)

Lead Sponsor Collaborator
Foundation for Prader-Willi Research Foundation for Prader-Willi Research Canada, Prader-Willi Research Foundation Australia, Prader-Willi Syndrome Association NZ, Prader-Willi Syndrome Association of Australia, Prader-Willi Syndrome Association USA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the incidence of serious medical events Serious medical events are those that result in death, are life-threatening, require hospitalization or an emergency room visit, or are medically significant Up to 4 years
Secondary Evaluate the incidence of non-serious thrombotic events Thrombotic events include blood clots in a blood vessel, such as an artery or vein Up to 4 years
Secondary Analyze D-dimer concentrations in a subset of participants who agree to provide a blood sample D-dimer is a protein in the blood that is present when a blood clot is forming or has formed Up to 4 years
Secondary Evaluate prescription medication use associated with serious medical events and thrombotic events Up to 4 years
Secondary Evaluate the change in weight Up to 4 years
Secondary Evaluate the change in height Up to 4 years
Secondary Evaluate the change in height-adjusted weight Up to 4 years
Secondary Evaluate PWS complexity using an online survey Up to 4 years
Secondary Evaluate the pattern of hyperphagia behaviors using an online survey Hyperphagia means the intense, constant hunger that often occurs in individuals with PWS Up to 4 years
Secondary Evaluate hyperphagia management using an online survey Up to 4 years
Secondary Evaluate food-related behaviors using an online survey Up to 4 years
Secondary Analyze medical information to evaluate the natural history of PWS Medical information will be from birth to before enrolling in the study Up to 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT05032326 - Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial Phase 3
Completed NCT04526379 - Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation N/A
Terminated NCT03458416 - A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome Phase 2
Active, not recruiting NCT05322096 - Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome Phase 2
Completed NCT02205450 - Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
Terminated NCT02179151 - Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Phase 3
Completed NCT00375089 - Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity N/A
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Recruiting NCT05879614 - An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) Phase 2
Recruiting NCT05938543 - Cerebellar TMS and Satiety in Prader-Willi Syndrome N/A
Recruiting NCT03031626 - Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Phase 4
Withdrawn NCT04086810 - An Open-Label Study of DCCR Tablet in Patients With PWS Phase 3
Completed NCT02629991 - Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome Phase 2
Recruiting NCT02297022 - Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome Phase 1
Not yet recruiting NCT02263781 - PREPL in Health and Disease N/A
Completed NCT00551343 - Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT05939453 - Impact of Bright Light Therapy on Prader-Willi Syndrome N/A
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Completed NCT03714373 - Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period Phase 3